| RECLAST® (ZOLEDRONIC ACID) PRESCRIBER | R ORDER I | FORM | | | | | | |
|--|---|---|--|---|---|---|--|--|
| Patient Name: | | | | Date of Birth: | | | | |
| Address: | | | | | | | | |
| Phone: | | Heig | ht: | □ inches | □ cm | Weight: | □ lbs □ kg | |
| | Clinica | l Informa | ation | | | | | |
| Primary Diagnosis Description: | | | | | ICD-10 | Code: | | |
| Is this the first dose? YES – date of first dose: NO – date of next dose due: NO – date of | | | | | | | | |
| Zole | dronic Acid | (Reclast ⁽ | B) Prescription | | | | | |
| ☐ Zoledronic Acid (Reclast) 5mg/100ml injection | | | | | | | | |
| Infuse 5mg/100ml IV once yearly Qty #1 | | | | | | | | |
| Administer over at least 15 minutes Flush with 10 ml 0.9% sodium chloride following | ng infusion | | | | | | | |
| | | | | | | | | |
| Ancillary Orders Anaphylaxis Kit | | | | | | | | |
| If this is a 1st infusion dose, would you like Option Care Health to provide an anaphylaxis kit with the 1st dose? | | | | | | | | |
| ☐ Yes ☐ No | | | | | | | | |
| Danasa | 45 to 20 loo) | 0 04 | /l / - 4.5. l) | \ CO == IN4 | 1 | | DDM | |
| Dosage: • Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SQ or IM x 1; repeat x 1 in 5 to 15 min PRN. | | | | | | | | |
| Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg – 25mg max dose) IV or IM; repeat x 1 in 15 min PRN no improvement. | | | | | | | | |
| • 0.9% Sodium Chloride 500 mL (> 30 kg) | or 250 mL (| ≤ 30 kg) l | V at KVO rate F | ² RN anaphyla | axıs. | | | |
| Other Medication Orders | | | | | | | | |
| Acetaminophen 650 mg PO 30 minutes prior | | Patient m | nay use own su | pply. | | | | |
| □ 0.9% sodium chloride 500mL via gravity after | intusion | | | | | | | |
| IV Flush Orders | | | | | | | | |
| | 0.9% Sodium Chloride 2 to 3 mL pre-/post-use. | | | | | | | |
| | um Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to | | | | | | | |
| mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed | | | | | | | | |
| Lab Orders | | | | | | | | |
| $\hfill\Box$ Baseline labs needed and drawn within 30 da | ys of order: | CBC w/d | iff, CMP, Phosp | horus, Magn | esium (| prescriber to arran | ge lab draw) | |
| □ Other: | | | | | | | | |
| Skilled nurse to administer doses intravenously in the ho infusing via Peripheral IV, skilled nurse to insert. | ome or alteri | nate care | setting. Refill | above ancilla | ary orde | ers as directed x 1 y | ear. If | |
| I certify that the use of the indicated treatm | ent is medic | ally nece | ssary, and I will | be supervisi | ng the p | atient's treatment | | |
| Prescriber Signature: | | | | | | Date: | | |
| | Prescrib | er Inforn | nation | | | | | |
| Prescriber Name: | | Phone: | | | Fax: | | | |
| Address: | | NPI: | | | | | | |
| City, State: Zip: | | | Office Contact: | | | | | |
| Fax completed form, insurance information, and clinical | documenta | tion to: | | | | | | |
| CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal informati | on related to a per | rson's health | care. It is being faxed to | o you after approp | riate autho | ization or under circumstan | ces that do not require | |
| authorization. You are obligated to maintain it in a safe, secure, and confidential mann Unauthorized re-disclosure or failure to maintain confidentiality could subject you to p whom it is addressed and may contain information that is privileged and confidential, agent responsible for delivering it to the intended recipient you are begreby notified it. | ner. Re-disclosure openalties described the disclosure of w | of this inform d in federal ar vhich is gover | ation is prohibited unlend state laws. IMPORT ned by applicable law. | ess permitted by la ANT WARNING: T If the reader of thi | w or appro his message is message | priate customer/patient aut e is intended for the use of t s not the intended recipient | thorization is obtained. the person or entity to t, or the employee or | |

agent responsible for delivering it to the intended recipient, you are hereby notified that please notify us immediately. Brand names are the property of their respective owners.